Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Nowbakht P, Roux S, Kassell N.

Stroke. 2012 Jun;43(6):1463-9. doi: 10.1161/STROKEAHA.111.648980. Epub 2012 Mar 8. Erratum in: Stroke. 2012 Jul;43(7):e68.

2.

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Lancet Neurol. 2011 Jul;10(7):618-25. doi: 10.1016/S1474-4422(11)70108-9. Epub 2011 Jun 2.

PMID:
21640651
3.

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A; CONSCIOUS-1 Investigators.

Stroke. 2008 Nov;39(11):3015-21. doi: 10.1161/STROKEAHA.108.519942. Epub 2008 Aug 7.

4.

Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF.

Neurocrit Care. 2010 Dec;13(3):416-24. doi: 10.1007/s12028-010-9433-3.

PMID:
20838933
5.

Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Acta Neurochir Suppl. 2013;115:27-31. doi: 10.1007/978-3-7091-1192-5_7.

PMID:
22890639
6.

Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.

Shen J, Pan JW, Fan ZX, Xiong XX, Zhan RY.

J Neurosurg. 2013 Jul;119(1):180-9. doi: 10.3171/2013.3.JNS121436. Epub 2013 May 3. Review.

PMID:
23641823
7.

Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.

Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ.

PLoS One. 2012;7(10):e47778. doi: 10.1371/journal.pone.0047778. Epub 2012 Oct 17.

8.
10.

Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.

Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, Vajkoczy P.

Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. Epub 2007 Aug 13.

PMID:
17700991
11.

Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.

Beck J, Raabe A.

Acta Neurochir Suppl. 2011;110(Pt 2):147-50. doi: 10.1007/978-3-7091-0356-2_26.

PMID:
21125461
12.

Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.

Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T.

Cerebrovasc Dis. 2017;44(1-2):59-67. doi: 10.1159/000475824. Epub 2017 May 3.

13.

Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study.

Pearl JD, Macdonald RL.

Acta Neurochir Suppl. 2008;105:207-10. Review.

PMID:
19066110
14.

Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage.

Ibrahim GM, Vachhrajani S, Ilodigwe D, Kassell NF, Mayer SA, Ruefenacht D, Schmiedek P, Weidauer S, Pasqualin A, Macdonald RL.

Neurosurgery. 2012 Jan;70(1):102-9; discussion 109. doi: 10.1227/NEU.0b013e31822e5a8e.

PMID:
21788917
15.

Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.

Vergouwen MD, Algra A, Rinkel GJ.

Stroke. 2012 Oct;43(10):2671-6. Epub 2012 Aug 7. Review. Erratum in: Stroke. 2013 Jun;44(6):e72.

16.

Stroke: disappointing results for clazosentan in CONSCIOUS-2.

Meyers PM, Connolly ES Jr.

Nat Rev Neurol. 2011 Oct 18;7(12):660-1. doi: 10.1038/nrneurol.2011.168. No abstract available.

PMID:
22009282
17.

Operative complications and differences in outcome after clipping and coiling of ruptured intracranial aneurysms.

Ayling OG, Ibrahim GM, Drake B, Torner JC, Macdonald RL.

J Neurosurg. 2015 Sep;123(3):621-8. doi: 10.3171/2014.11.JNS141607. Epub 2015 Jun 5.

PMID:
26047409
18.

Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.

Macdonald RL.

Expert Opin Investig Drugs. 2008 Nov;17(11):1761-7. doi: 10.1517/13543784.17.11.1761 .

PMID:
18922111
19.

Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.

Sabri M, Ai J, Macdonald RL.

Stroke. 2011 May;42(5):1454-60. doi: 10.1161/STROKEAHA.110.604728. Epub 2011 Mar 31.

20.

Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.

Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, Lakovic K, Wan H, Macdonald RL.

Brain Res. 2011 May 25;1392:132-9. doi: 10.1016/j.brainres.2011.03.068. Epub 2011 Apr 3.

PMID:
21466789

Supplemental Content

Support Center